1,2-Ethanediamine, N-(2-aminoethyl)-N'-propyl- | 118408-20-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,2-Ethanediamine, N-(2-aminoethyl)-N'-propyl-
• 英文别名: N'-[2-(propylamino)ethyl]ethane-1,2-diamine
• CAS: 118408-20-1
• 化学式: C₇H₁₉N₃
• 分子量: 145.25
• InChiKey: IPMWIVQWGGRTLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• FATTY ACID AMIDES, COMPOSITIONS AND METHODS OF USE
  申请人：Milne Jill C.

  公开号：US20130059801A1

  公开（公告）日：2013-03-07

  The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administration of an effective amount of a fatty acid amide.

  本发明涉及脂肪酸酰胺；包含有效量的脂肪酸酰胺的组合物；以及治疗或预防癌症、代谢性疾病或神经退行性疾病的方法，其中包括给予有效量的脂肪酸酰胺。
• LIPID CONTAINING FORMULATIONS
  申请人：Manoharan Muthiah

  公开号：US20090023673A1

  公开（公告）日：2009-01-22

  Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.

  本文介绍了用于管理基于核酸的治疗的组合物和方法，例如关联复合物，如脂质体和脂质复合物。
• Novel compounds and compositions as cathepsin inhibitors
  申请人：Graupe Michael

  公开号：US20070049594A1

  公开（公告）日：2007-03-01

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新型选择性卡普林S抑制剂，其药物可接受的盐和N-氧化物，以及它们作为治疗剂的用途和制备方法。
• Dielectric Materials and Methods of Preparation and Use Thereof
  申请人：Zheng Yan

  公开号：US20110175089A1

  公开（公告）日：2011-07-21

  Disclosed are dendritic macromolecule-based dielectric compositions (e.g., formulations) and materials (e.g. films) and associated devices. The dendritic macromolecules have branched ends that are functionalized with an organic group that includes at least one 3-40 membered cyclic group.

  本发明涉及基于树枝状大分子的介电组合物（例如配方）和材料（例如薄膜）及其相关设备。所述树枝状大分子具有带有至少一个3-40环成员的有机基团的分支末端。
• TREATMENT OF MITOCHONDRIA-RELATED DISEASES AND IMPROVEMENT OF AGE-RELATED METABOLIC DEFICITS
  申请人：Cooper Garth James Smith

  公开号：US20130108709A1

  公开（公告）日：2013-05-02

  Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

  药物组合物和治疗方法，用于治疗患有或有风险患有各种疾病、疾病和疾病的受试者，包括线粒体相关疾病、疾病和疾病，包括呼吸链障碍，以及与线粒体肿胀、线粒体功能障碍、线粒体泄漏、氧化应激、线粒体数量增加、线粒体和线粒体相关蛋白质质量增加以及线粒体和相关蛋白质表达增加至少部分有关的疾病、疾病和疾病。